Skip to main content
Menu

AlphaLISA SureFire Ultra Human and Mouse Phospho-FOXO1 (Ser256) Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Phospho-FOXO1 (Ser256) assay is a sandwich immunoassay for quantitative detection of phospho-FOXO1 (Ser256) in cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 10 µL

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Phospho-FOXO1 (Ser256) assay is a sandwich immunoassay for quantitative detection of phospho-FOXO1 (Ser256) in cellular lysates using Alpha Technology.

Product variants
Unit Size: 100 Assay Points
Part #:
ALSU-PFOXO1-A-HV
List price
USD 722.00
Your online price:
Unit Size: 500 Assay Points
Part #:
ALSU-PFOXO1-A500
List price
USD 2,441.00
Your online price:
Unit Size: 10,000 Assay Points
Part #:
ALSU-PFOXO1-A10K
List price
USD 14,688.00
Your online price:
Unit Size: 50,000 Assay Points
Part #:
ALSU-PFOXO1-A50K
List price
USD 46,690.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Overview

Forkhead Box O1 (FOXO1) is a transcription factor that regulates genes involved in glucose metabolism, cell cycle arrest, apoptosis, and oxidative stress resistance. FOXO1 activity is controlled by AKT-mediated phosphorylation, which promotes nuclear exclusion and proteasomal degradation. Dephosphorylated FOXO1 translocates to the nucleus and activates target genes including glucose-6-phosphatase, PEPCK, and p27Kip1. FOXO1 plays critical roles in hepatic gluconeogenesis and functions as a tumor suppressor in cancer. Dysregulation of FOXO1 is implicated in type 2 diabetes and cancer, making it a therapeutic target for metabolic disorders and malignancies.

The AlphaLISA SureFire Ultra Human and Mouse Phospho-FOXO1 (Ser256) is a sandwich immunoassay for the quantitative detection of phospho-FOXO1 (Ser256) in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

How it works

Phospho-AlphaLISA SureFire Ultra assay principle

The Phospho-AlphaLISA SureFire Ultra assay measures a protein target when phosphorylated at a specific residue.

The assay uses two antibodies which recognize the phospho epitope and a distal epitope on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of phosphoprotein present in the sample.

assay principle Phospho AlphaLISA Surefire Ultra

 

Phospho-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Phospho-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2 plates assay protocol alphalisa surefire ultra phospho assay

Phospho-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Phosphorylated target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1 plate assay protocol alphalisa surefire ultra phospho assay

Assay validation

Insulin induces FOXO1 phosphorylation in a dose-dependent manner

MCF7 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were starved for 2 hours and treated with increasing concentrations of insulin for 5 minutes prepared in serum free medium.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). FOXO1 Phospho (Ser256) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, insulin triggered a dose-dependent increase in the levels of Phospho FOXO1 (Ser256) with no significant changes in Total levels.

Pharmacological Validation (activator) of Phospho-FOXO1 (Ser256)

Razuprotafib induces FOXO1 phosphorylation in HUVEC cells

HUVEC cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were starved for 2 hours and treated with increasing concentrations of Razuprotafib for 15 minutes.

After treatment, the cells were lysed with 25 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). FOXO1 Phospho (Ser256) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 12,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Razuprotafib treatment results in the activation of the Tie2 signaling pathway in endothelial cells and a dose-dependent increase in the levels of Phospho FOXO1 (Ser256) with no significant changes in Total levels.

Pharmacological Validation (activator) of Phospho-FOXO1 (Ser256)

Insulin growth factor induces FOXO1 phosphorylation in MCF7 cells

MCF7 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were starved for 2 hours and treated 500 ng/mL of IGF-1 for 5 minutes prepared in serum free medium.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). FOXO1 Phospho (Ser256) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IGF-1 increased the levels of Phospho FOXO1 (Ser256) with no significant changes in Total levels (data not shown).

Pharmacological Validation (activator) of Phospho-FOXO1 (Ser256)

Decrease in FOXO1 phosphorylation by PI3K inhibitor

HEK293 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with 50 µM LY294002 for 24 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). FOXO1 Phospho (Ser256) levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, LY294002 treatment resulted in a decrease of phosphorylated FOXO1 at Ser256.

Pharmacological Validation (inhibitor) of Phospho FOXO1

Assay specificity/selectivity

Knockout validation of Phospho FOXO1 (Ser256) assay

Phospho FOXO1 (Ser256) levels were assessed in HAP1 wild type (WT) and FOXO1 knockout (KO) cells. Cells were cultured to confluency in T175 flasks at 37°C, 5% CO2. Cells were lysed in 4 mL of Lysis Buffer.

Lysates were serially diluted in Lysis Buffer and FOXO1 Phospho (Ser256) levels were evaluated using the AlphaLISA SureFire Ultra kit. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Phospho FOXO1 (Ser256) was only detected in WT cells, confirming assay specificity.

Specificity validation of FOXO1 Phospho (Ser256) assay

Assay sensitivity

Assay sensitivity - cell lysate

Cell lysate was prepared from HEK293 cells cultured to confluency in a T175 flask and lysed in 3 mL of Lysis Buffer for 10 minutes at RT with shaking.

Lysate was serially diluted in Lysis Buffer and assayed for Phospho (Ser256) and Total FOXO1 levels using respective AlphaLISA SureFire Ultra kits. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Approximate number of cells/datapoint is indicated on the graph. The dotted line represents assay background. This assay can detect Phospho (Ser256) in approximately 2,500 cells/datapoint.

Assay sensitivity of Phospho (Ser256) FOXO1

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Product Group
Kit
Protocol Time
2h at RT
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
FOXO1
Target Class
Phosphoproteins
Target Species
Human
Mouse
Technology
Alpha
Therapeutic Area
Metabolic
Neuroscience
Oncology
Unit Size
500 Assay Points

Resources

Are you looking for resources, click on the resource type to explore further.

1-3 of 3 Resources
Brochure Icon
Brochure
Alpha assays and reagents catalog

Alpha technolgy enables the rapid and straightforward mesaure of virtually any target. This includes enzymes, receptor-ligand...

Brochure Icon
Brochure
Alpha SureFire Ultra no-wash immunoassay catalog

Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...

Brochure Icon
Brochure
Species compatibility for HTRF, AlphaLISA SureFire Ultra and Alpha SureFire Ultra Multiplex assays

This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...

Loading...

Scroll Icon

Revvity AI Assistant Beta